Abstract: A novel prophylactic therapy for cancer, as well as therapy against DNA damage, inflammation and immunosuppression involves the ?-blocker carvedilol, which is a racemic mixture consisting of two enantiomers, S- and R-carvedilol, in 1:1 ratio. S-carvedilol is a ?-blocker, with a highly potent antagonizing activity against the ?-adrenergic receptors, which is the main mechanism for the drug's pharmacological activity in treatment of high blood pressure and heart failure. Carvedilol—the racemic mixture—prevents ultraviolet radiation induced skin cancer by attenuating DNA damage, reducing inflammation and reversing immunosuppression. The non-?-blocking enantiomer R-carvedilol exhibits the same cancer preventive efficacy as the racemic carvedilol, without disturbing the cardiovascular system. Both carvedilol and R-carvedilol prevent chemical carcinogen-induced lung cancer development and lung inflammation.

Abstract: Embodiments of the disclosed technologies include, responsive to a first use of a first application by a first user, configuring, in a first prompt, at least one instruction based on first application context data and first user context data. The first prompt is stored in a memory that is accessible to the first application and a second application. Via the second application, first output of a generative artificial intelligence (GAI) model is presented to the first user. Based on the first output of the GAI model, at least one second use of the first application by the first user, or at least one first use of a third application by the first user, is configured.

Abstract: Embodiments herein are directed to an occlusion device that includes a body, a pair of lobes, and an adjustment assembly. One of the pair of lobes positioned at a distal portion of the body and the other one is positioned at a proximal portion. The body includes an adjustment assembly positioned between the distal and the proximal portions to change a distance between the pair of lobes. The adjustment assembly includes a receiving member and an elongated member. The elongated member is configured to move the body between an extended position and a retracted position, such that in the retracted position, the elongated member is received within an inner diameter of the receiving member. In the extended position, the elongated member is extended away from a first end of the receiving member such that the distance between the pair of lobes is increased.

Abstract: The present disclosure relates to formulations for coating a balloon of a balloon catheter, the formulations including one or more groups of microparticles that include a therapeutic agent. In some aspects, the microparticles are polymer microparticles with the therapeutic dispersed therein or crystalline microparticles of the therapeutic agent. In some aspects, the formulations further include an antioxidant and/or an excipient.

Abstract: A vascular occlusion device includes a plurality of radially-extending segments and a plurality of angled bends connecting ends of two or more radially-extending segments of the plurality of radially-extending segments. Each angled bend may define a contact point configured to anchor to a vessel wall. The vascular occlusion device may be configurable between an unexpanded state and an expanded state, and when the vascular occlusion device is in the expanded state, the plurality of angled bends expand such that the contact points contact the vessel wall. The contact points may define a width of the vascular occlusion device in a direction perpendicular to a length of the vascular occlusion device. The width may be configured to correspond to a diameter of a blood vessel.

Abstract: The neuron Logic Gate Metal-Oxide-Semiconductor (?LGMOS) circuits to mimic neurons' “integrate-and-fire” behaviors in biological neural network system can be fabricated with industry Complementary Metal-Oxide Semiconductor (CMOS) logic process technology, with which digital computational circuits are fabricated. A processing system having analog ?LGMOS circuits, conversion circuitry and digital circuits optimized for power and cost for varieties of applications can be then fabricated with the same CMOS logic process technology for IC chips. Meanwhile analog ?LGMOS circuits inspired from biological neural network systems can be simulated, designed, and fabricated for IC chips for the applications of biomedical fields.

Abstract: The present disclosure concerns drug coating layers for medical devices that cover an exterior surface or portion thereof. The drug coating layers include a bioabsorbable material with a therapeutic or a polymer microparticle loaded with a therapeutic embedded therein. As the material is bioabsorbed the therapeutic is released and available to provide localized activity in a subject. In some aspects, the drug coating layer is of a material that due to the body temperature of the subject becomes tacky and allows for adhesion to the vessel wall.

Abstract: In some implementations, a system may receive, from a first user, data associated with a new database entry to be added to a master database that is associated with multiple sets of users having different access permissions to entries in the master database. The system may write the data to a first repository, write an entry including the data to a master repository, and generate a record of the entry. The system may receive, from a second user, additional data associated with the new database entry. The system may write the additional data to a second repository, modify the entry in the master repository based on the additional data, and generate a record of the modified entry. The system may perform verifications and output a notification based on the verifications. The system may further output, to a public repository, the modified entry with at least one data value removed.

Abstract: A variable gain amplifier system includes a variable gain amplifier circuit configured to receive an input signal, apply a gain to the input signal, and generate an output signal in accordance with the gain applied to the input signal. The variable gain amplifier circuit is further configured to receive a gain control signal and a bandwidth control signal. A control module is configured to generate the gain control signal to adjust the gain of the variable gain amplifier circuit and generate, separately from the gain control signal, the bandwidth control signal to adjust a bandwidth of the variable gain amplifier circuit by selectively varying an amount of inductance contributed by an inductor circuit of the variable gain amplifier circuit.

Abstract: Drug-loaded microbead compositions include microbeads of a water-swellable polymer material and a complex of a carrier and a therapeutic agent chemically bonded to the carrier. The complex is embedded in the polymer material. Methods for preparing the drug-loaded microbead compositions and embolization compositions include loading a therapeutic agent into a water-swellable polymer material to form microbeads, then removing water from the microbeads. Additional drug-loaded microbead compositions include microbeads of a biodegradable material, vesicular agents, a first therapeutic agent associated with the vesicular agents, and a second therapeutic agent different from the first therapeutic agent. The vesicular agents include a lipid bilayer surrounding a vesicular core. The second therapeutic agent is contained within the microbeads or associated with the microbeads through ionic or non-covalent interaction and may or may not be associated with the vesicular agents.

Abstract: In some implementations, a system may receive, from a first user, data associated with a new database entry to be added to a master database that is associated with multiple sets of users having different access permissions to entries in the master database. The system may write the data to a first repository, write an entry including the data to a master repository, and generate a record of the entry. The system may receive, from a second user, additional data associated with the new database entry. The system may write the additional data to a second repository, modify the entry in the master repository based on the additional data, and generate a record of the modified entry. The system may perform verifications and output a notification based on the verifications. The system may further output, to a public repository, the modified entry with at least one data value removed.

Abstract: Drug-loaded microbead compositions include microbeads of a biodegradable material and vesicular agents located within or associated with the biodegradable material of the microbeads. The vesicular agents include a lipid bilayer and comprise liposomes or ethosomes. The drug-loaded microbeads include a first therapeutic agent associated with the vesicular agents, and a second therapeutic agent different from the first therapeutic agent. The vesicular agents include a lipid bilayer surrounding a vesicular core. The second therapeutic agent is contained within the microbeads or associated with the microbeads through ionic or non-covalent interaction and may or may not be associated with the vesicular agents. Drug-loaded biodegradable microbead compositions include microbeads of biodegradable material and a therapeutic agent.

Abstract: Medical devices such as stents, stent grafts, and balloon catheters include a coating layer applied over a modified exterior surface of the medical device. The modified exterior surface comprises an exterior surface of the medical device subjected to a surface modification that decreases a surface free energy of the exterior surface before application of the coating layer an exterior surface. The coating layer comprises a hydrophobic therapeutic agent and at least one additive. The modified exterior surface may affect the release kinetics of the drug from the device, the crystallinity of the drug layer, the surface morphology of the coating and particle shape, or the particle size of drug of a therapeutic layer in the coating layer. For example, the effects caused by the modified exterior surface may increase the retention time and amount of therapeutic agent in tissue.

Abstract: In some implementations, a system may receive, from a first user, data associated with a new database entry to be added to a master database that is associated with multiple sets of users having different access permissions to entries in the master database. The system may write the data to a first repository, write an entry including the data to a master repository, and generate a record of the entry. The system may receive, from a second user, additional data associated with the new database entry. The system may write the additional data to a second repository, modify the entry in the master repository based on the additional data, and generate a record of the modified entry. The system may perform verifications and output a notification based on the verifications. The system may further output, to a public repository, the modified entry with at least one data value removed.

Abstract: The application is to antibodies which have been labelled with polyenzymes (multiple enzymes), specifically polyperoxidases, for use in direct immunohistochemical assays of tissues. The antibodies used diagnostically may also be antibodies which are used therapeutically.

Abstract: Drug-loaded microbead compositions including a plurality of individual microbeads of a biodegradable material, a plurality of individual vesicular agents, a first therapeutic agent, and a second therapeutic agent different from the first therapeutic agent. The vesicular agents include at least one lipid bilayer surrounding a vesicular core. The first therapeutic agent is associated with the individual vesicular agents. For example, the first therapeutic agent may be contained within the individual vesicular agents or may be associated with the individual vesicular agents by ionic or non-covalent interaction. The second therapeutic agent is different from the first therapeutic agent and contained within the individual microbeads or associated with the individual microbeads through ionic or non-covalent interaction. The second therapeutic agent may or may not be associated with the individual vesicular agents.

Abstract: The present disclosure relates to transparent ready-to-use hair bleaching compositions and compositions useful for preparing the transparent ready-to-use hair bleaching compositions. The transparent ready-to-use bleaching compositions typically include: (i) one or more oxidizing agents selected from the group consisting of persulfates, perborates, percarbonates, a salt thereof, and a mixture thereof; (ii) one or more non-acrylic thickening polymers; (iii) one or more acrylic polymers; (iv) hydrogen peroxide; (v) one or more polyurethane polyethers; and (vi) water. Kits and methods for bleaching hair also disclosed.

Abstract: A semiconductor package structure includes a first redistribution layer, a plurality of conductive connectors, a chip, and an encapsulant. The first redistribution layer has a first surface and a second surface opposite to the first surface. The first redistribution layer includes at least one conductive pattern and at least one dielectric layer stacked on each other. The conductive pattern includes a plurality of landing pads, and each of the landing pads is separated from the dielectric layer. The conductive connectors are located on the first surface. Each of the conductive connectors is corresponding to and electrically connected to one of the landing pads. The chip is located on the first surface. The chip is electrically connected to the first redistribution layer. The encapsulant encapsulates the chip and the conductive connectors. A manufacturing method of a semiconductor package structure is also provided.

Abstract: A novel prophylactic therapy for cancer, as well as therapy against DNA damage, inflammation and immunosuppression involves the ?-blocker carvedilol, which is a racemic mixture consisting of two enantiomers, S- and R-carvedilol, in 1:1 ratio. S-carvedilol is a ?-blocker, with a highly potent antagonizing activity against the ?-adrenergic receptors, which is the main mechanism for the drug's pharmacological activity in treatment of high blood pressure and heart failure. Carvedilol—the racemic mixture—prevents ultraviolet radiation induced skin cancer by attenuating DNA damage, reducing inflammation and reversing immunosuppression. The non-?-blocking enantiomer R-carvedilol exhibits the same cancer preventive efficacy as the racemic carvedilol, without disturbing the cardiovascular system. Both carvedilol and R-carvedilol prevent chemical carcinogen-induced lung cancer development and lung inflammation.

Abstract: The present invention is directed electrical circuits. According to a specific embodiment, the present invention provides a variable gain amplifier that includes a first switch, which includes drain terminal coupled to an inductor. A second switch is configured in parallel to the inductor, and the resistance value of the second switch is adjustable in response to a control signal. There are other embodiments as well.